Carbon Universe Spółka z Ograniczoną Odpowiedzialnością (KRS 0001008593, NIP 7393977243) is a Polish company, headquartered in Elbląg, Warmińsko-Mazurskie voivodeship. Carbon Universe operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since December 16, 2022.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Carbon Universe
Identity
- Name
- Carbon Universe Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- December 16, 2022
- Registry status as of
- December 16, 2025
- Latest entry
- December 15, 2025
- Founding act
- 14.12.2022 R.
Articles of association history (2)
- December 14, 2022: 14.12.2022 R.
- December 9, 2023: UCHWAŁĄ NR 2/12/2023 Z DNIA 09.12.2023R. ZMIENIONO §2 I §3 UMOWY SPÓŁKI
Activities
Other activities
Address and contact
- Address
- UL. 12 LUTEGO, 25, 7, 82-300, ELBLĄG, POLSKA
- Voivodeship
- WARMIŃSKO-MAZURSKIE
- District
- ELBLĄG
- PATRYK.SZYMCZAK@GMAIL.COM
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-27161-40645-TGRTB-27
- Coordinates
- 54.1564, 19.4000approx.
Operational status - Carbon Universe
Founded
December 16, 2022
3 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
ELBLĄG
WARMIŃSKO-MAZURSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
50 shares total
Shareholders
1
shareholder
Board
1 person
Registry entries
9
latest: December 15, 2025
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Carbon Universe.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
